Novartis Says Phase 3 Data Show Sustained Rhapsido Efficacy in Chronic Inducible Urticaria

MT Newswires Live11-13

Novartis (NVS) said Thursday results of a phase 3 trial of Rhapsido showed sustained efficacy through 52 weeks in adult patients across three subtypes of chronic inducible urticaria.

The company said patients who switched from placebo to Rhapsido at week 24 had response rates at week 52 similar to those who received the drug from the start.

The complete or partial response rates at week 52 in patients receiving Rhapsido were 46.8%, 83.3% and 58.2% in the symptomatic dermographism, cold urticaria and cholinergic urticaria cohorts, respectively, compared with 47.7%, 88.9% and 69.8% in patients who switched to Rhapsido from placebo, according to a statement.

Rhapsido was well tolerated through week 52, with a safety profile consistent with previous studies, Novartis said.

Price: 160.54, Change: +0.22, Percent Change: +0.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment